DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

DEXMEDETOMIDINE (DEXMEDETOMIDINE HYDROCHLORIDE)

Prieinama:

EUGIA PHARMA INC.

ATC kodas:

N05CM18

INN (Tarptautinis Pavadinimas):

DEXMEDETOMIDINE

Dozė:

100MCG

Vaisto forma:

SOLUTION

Sudėtis:

DEXMEDETOMIDINE (DEXMEDETOMIDINE HYDROCHLORIDE) 100MCG

Vartojimo būdas:

INTRAVENOUS

Vienetai pakuotėje:

100

Recepto tipas:

Prescription

Produkto santrauka:

Active ingredient group (AIG) number: 0152679003; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2022-07-08

Prekės savybės

_Page 1 of 32_
PRODUCT MONOGRAPH
PR DEXMEDETOMIDINE HYDROCHLORIDE FOR INJECTION
CONCENTRATE
DEXMEDETOMIDINE (AS DEXMEDETOMIDINE HYDROCHLORIDE)
200 MCG/2 ML (100 MCG/ML)
Alpha
2
-adrenergic agonist
EUGIA PHARMA INC.
3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario
L4L 8K8 Canada
SUBMISSION CONTROL NO.: 264435
Date of
Preparation:
July 8, 2022
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
8
DRUG INTERACTIONS
.........................................................................................................
12
DOSAGE AND ADMINISTRATION
.....................................................................................
13
OVERDOSAGE
........................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
16
STORAGE AND STABILITY
.................................................................................................
19
SPECIAL HANDLING
INSTRUCTION...................................................................................19
DOSAGE FORM, COMPOSITION AND
PACKAGING………………………………….20
PART II: SCIENTIFIC INFORMATION
...............................................................................
21
PHARMACEUTICAL INFORMATION
...................